Please assess the completion status of the following clinical trial:

Trial Title: The SCCS Polypill Pilot Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Enrolled at the SCCS site in Mobile, Alabama, obtain care at Franklin Primary Health Center, or live in the surrounding area.~* Aged 45-75 years~* Baseline systolic blood pressure ≥120 mm Hg. In this open-label trial, the study physicians are permitted to prescribe any additional medication deemed appropriate to achieve blood pressure control.~Exclusion Criteria:~* History of coronary heart disease or stroke~* History of cancer, except for basal cell skin cancer~* History of liver disease, not including chronic, clinically-stable hepatitis~* Laboratory evidence of hepatic dysfunction (an alanine aminotransferase level more than two times the upper limit of the normal range)~* Known renal disease, estimated creatinine clearance \< 60~* Current use of more than 2 anti-hypertensive medications~* LDL cholesterol ≥190 mg/dl~* Insulin-dependent diabetes~* Known intolerance to any of the components of the polypill~* Potassium \<3.4 or \>5.5 mEq/L~* Use of medications that interact with statins, including those affecting the cytochrome P450 system~* Current use of diuretics for indications other than hypertension~* Comorbidities that might be expected to limit lifespan during the 12-month follow-up period~* Inability to provide consent.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving.
- Polypill (Type: EXPERIMENTAL): The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.~Polypill will be taken once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).